PTC Therapeutics, Inc. News Releases http://ir.ptcbio.com/ PTC Therapeutics, Inc. News Releases en PTC Therapeutics Receives FDA Approval for the Expansion of the EMFLAZA® (deflazacort) Labeling to Include Patients 2-5 Years of Age http://ir.ptcbio.com/news-releases/news-release-details/ptc-therapeutics-receives-fda-approval-expansion-emflazar -- Emflaza is the only approved treatment for all patients two and over living with Duchenne muscular dystrophy -- SOUTH PLAINFIELD, N.J. , June 7, 2019 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the U.S. Food and Drug Administration ( FDA ) approved the company's Fri, 07 Jun 2019 13:31:00 -0400 PTC Therapeutics, Inc. News Releases 12076 PTC Therapeutics Promotes Emily Hill to Chief Financial Officer http://ir.ptcbio.com/news-releases/news-release-details/ptc-therapeutics-promotes-emily-hill-chief-financial-officer SOUTH PLAINFIELD, N.J. , June 3, 2019 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the promotion of Emily Hill to Chief Financial Officer. Ms. Hill joined PTC Therapeutics in November 2013 and was most recently Senior Vice President and Head of Investor Relations. Mon, 03 Jun 2019 08:00:00 -0400 PTC Therapeutics, Inc. News Releases 12046 PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) http://ir.ptcbio.com/news-releases/news-release-details/ptc-therapeutics-reports-inducement-grants-under-nasdaq-45 SOUTH PLAINFIELD, N.J. , May 31, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on May 20, 2019 it approved non-statutory stock options to purchase an aggregate of 76,250 shares of its common stock to 15 new employees.  The awards were made pursuant to the NASDAQ Fri, 31 May 2019 16:30:00 -0400 PTC Therapeutics, Inc. News Releases 12041 PTC Therapeutics to Participate at Upcoming Investor Conference http://ir.ptcbio.com/news-releases/news-release-details/ptc-therapeutics-participate-upcoming-investor-conference-4 SOUTH PLAINFIELD, N.J. , May 30, 2019 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the Jefferies Healthcare Conference on Thursday, June 6th at 4:00 p.m. ET . The presentation will be webcast live on the Events and Thu, 30 May 2019 08:00:00 -0400 PTC Therapeutics, Inc. News Releases 12036 PTC Therapeutics Announces First-Ever Winners of Its PRIORITY Program To Support Research Projects In Rare, Genetic Disorders http://ir.ptcbio.com/news-releases/news-release-details/ptc-therapeutics-announces-first-ever-winners-its-priority - $545,000 awarded to help improve Duchenne muscular dystrophy diagnosis and screening across the globe - SOUTH PLAINFIELD, N.J. , May 20, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the three funding recipients from PRIORITY, an annual program to support outstanding Mon, 20 May 2019 08:00:00 -0400 PTC Therapeutics, Inc. News Releases 12016 PTC Therapeutics and MRI Interventions Announce Strategic Investment http://ir.ptcbio.com/news-releases/news-release-details/ptc-therapeutics-and-mri-interventions-announce-strategic - $4 million equity investment to advance delivery device R&D for CNS gene therapy portfolio and other company operations - SOUTH PLAINFIELD, N.J. and IRVINE, Calif. , May 9, 2019 /PRNewswire/ --   PTC Therapeutics, Inc. (NASDAQ: PTCT) and MRI Interventions, Inc. Thu, 09 May 2019 16:05:00 -0400 PTC Therapeutics, Inc. News Releases 12011 PTC Therapeutics to Participate at Upcoming Investor Conferences http://ir.ptcbio.com/news-releases/news-release-details/ptc-therapeutics-participate-upcoming-investor-conferences-6 SOUTH PLAINFIELD, N.J. , May 8, 2019 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the following conferences: Bank of America Merrill Lynch Healthcare Conference Tuesday, May 14 th at 1:40 p.m. Wed, 08 May 2019 08:00:00 -0400 PTC Therapeutics, Inc. News Releases 11996 Data from Pivotal FIREFISH and SUNFISH Studies Demonstrate Clinical Benefit of Risdiplam in Type 1, 2, & 3 Spinal Muscular Atrophy Patients http://ir.ptcbio.com/news-releases/news-release-details/data-pivotal-firefish-and-sunfish-studies-demonstrate-clinical Babies with Type 1 SMA from Part 1 of FIREFISH continue to achieve motor milestones including standing 58% of patients experienced an improvement of at least 3 points on MFM32 scale vs. baseline after 12 months of treatment in Part 1 of SUNFISH No drug related safety findings leading to withdrawal Tue, 07 May 2019 01:00:00 -0400 PTC Therapeutics, Inc. News Releases 11971 PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) http://ir.ptcbio.com/news-releases/news-release-details/ptc-therapeutics-reports-inducement-grants-under-nasdaq-44 SOUTH PLAINFIELD, N.J. , May 3, 2019 /PRNewswire/ --  PTC Therapeutics, Inc.  (NASDAQ: PTCT) today announced that on April 23, 2019 it approved non-statutory stock options to purchase an aggregate of 210,900 shares of its common stock to 27 new employees. Fri, 03 May 2019 16:30:00 -0400 PTC Therapeutics, Inc. News Releases 11961 PTC Therapeutics Reports First Quarter 2019 Financial Results and Provides a Corporate Update http://ir.ptcbio.com/news-releases/news-release-details/ptc-therapeutics-reports-first-quarter-2019-financial-results Translarna™ Approved by Brazilian Health Regulatory Authority (ANVISA) Waylivra™ Receives Positive CHMP Opinion SOUTH PLAINFIELD, N.J. , May 2, 2019 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the first quarter ending Thu, 02 May 2019 16:01:00 -0400 PTC Therapeutics, Inc. News Releases 11946